Hikal Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sb0umfpj6yhmlx2152p8kl6n.pdf

Key Takeaways


The Margin Shock: What Happened and When It Recovers

Anish Swadi: "Q1 overall for the company as we look at it will certainly be more subdued than Q4. ... Q1 will probably bottom out and then you will have an improvement in Q2 and then you will see an increase in Q3 and Q4 going forward."

Pharma: Destocking Masks Underlying CDMO Momentum

Manoj Mehrotra: "We would also not like to really sell at very low prices and build up inventory at customers' end. So, it's better to be a little slow and steady and make sure that the cost is passed on over a period of time."

Crop Protection: Near-Term Growth Engine with Faster Asset Turns


Regulatory Overhang: Taloja Closure and Sachin Incident


Strategy and CAPEX: Consolidation Before Acceleration

Anish Swadi: "We expect FY23 to be a year of necessary slowdown and consolidation to prepare us for future accelerated growth."

Guidance & Commitments

CommitmentSpecificsTimeline
Margin bottomQ1 FY23 will be more subdued than Q4 FY22 and "probably bottom out"Q1 FY23
Margin recovery pathStepwise improvement Q2 through Q4 FY23; hopeful of normal marginsFY24
Pharma price pass-throughImpact of customer price discussions to be seenFY23
Pharma base business recoveryCDMO base business to return to prior levelsFrom Q2 FY23
Pharma new product launchesFour to five products from a pipeline of ten-plusFY23
Animal Health plant commissioningPlant complete, revenue accrual beginsFY23 commissioning; FY24 revenue
Fungicide plant commissioningFirst fungicide plant complete, revenue startsEnd of Q3 CY2022; revenue by end FY23
Second fungicide launchCombined potential of ₹400–500 crore from two fungicidesNot specified
CAPEX cash outflow₹250–270 crore, focused on essential and customer-backed projectsFY23
Long-term segment growthBoth divisions to grow at 15%From FY24 onwards
Long-term margin target~20% consolidated, with 50–100 bps annual improvementFrom FY24 onwards
FY25 revenue potentialAround ₹3,000 crore described as "possible"FY25
Taloja plant reopeningPending order book execution begins; gradual ramp-upUpon MPCB clearance

Key Metrics

MetricQ4 FY22
Consolidated total revenue₹1,943 cr (FY22), +13% YoY
Profit before tax₹341 cr (FY22), +5% YoY
EBITDA margin17.6% (FY22); 9M FY22 was 19.6% vs 18% in 9M FY21
Pharma revenue₹1,130 cr (FY22), +6.6% YoY
Pharma EBIT margin13.4% (FY22)
Crop protection revenue₹813 cr (FY22), +23% YoY
Crop protection EBIT margin14.3% (FY22)
Debt-to-equity ratio0.59x, improved from 0.61x in FY21 and 0.73x the year prior
Average borrowing cost6.15% blended rate (Mar 2022), down from 6.99% in Mar 2021
Return on equity16.2% (FY22), improved from 15.2% in FY21
Total dividend80% or ₹1.60 per share (FY22)
Total debt₹675 cr (Mar 2022): ₹273 cr working capital, ₹402 cr long-term
FY23 expected capex cash outflow₹250–275 cr
FY23 expected capex capitalization~₹400 cr
Taloja facility revenue contribution₹260–280 cr